OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Cant even find a worthwhile comment. Good RNS - SP drops and with very much lower volumns than is daily normal. Patience is required.

Sanofi-Aventis to start seeking regulatory approval next yr for new cancer drug
AFX


PARIS (Thomson Financial) - Sanofi-Aventis said it will start the process of seeking regulatory approval as early as next year for marketing its Aflibercept cancer drug. It said results with ovarian and lung cancer patients were 'very promising' ahead of a large Phase 3 trial that will occur this year.

Sanofi also said its S-1 drug, developed with Taiho, showed 'impressive activity' in gastric cancer trials, and test results from its TroVax anti-cancer vaccine, developed jointly with Oxford Biomedica, were 'encouraging.'

In data presented at a medical conference, the company said other studies showed the effectiveness of its Eloxatin drug against colon and colorectal cancer, and of its Taxotere drug in against breast cancer.

tfn.paris@thomson.com

mjs/jag



COPYRIGHT



Copyright AFX News Limited 2007. All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

i have added a link to an interview on Pharma Television with Nick Woolf, SVP Corporate Strategy, Oxford BioMedica to the media coverage page: good viewing

http://www.oxfordbiomedica.co.uk/media.htm

micky468 -
Cheers.

http://www.pharmatelevision.com/video/522/288/pvbr_f2f26_woolf.wmv

OXFORD BIOMEDICA AND SIGMA-ALDRICH ISSUE JOINT LICENCE FOR LENTIVECTOR(R)
TECHNOLOGY TO MAJOR BIOTECHNOLOGY COMPANY

Commenting on the news, Oxford BioMedica's Senior Vice President Commercial
Development, Peter Nolan, said: 'We are delighted to have secured another
licensee for the LentiVector gene delivery technology, which has become the
industry gold standard for various applications in research and drug discovery.
With our strategic partner, Sigma-Aldrich, we believe that the technology has
significant commercial potential as a research tool, which is in addition to its
application in gene-based therapies.'

http://moneyam.uk-wire.com/cgi-bin/articles/200707020700483769Z.html

I especially like this statement: "...for the LentiVector gene delivery technology, which has become the industry gold standard for various applications in research and drug discovery."

Oxford Biomedica PLC
06 July 2007
OXFORD BIOMEDICA SECURES RIGHTS TO ENDOSTATIN AND ANGIOSTATIN GENES FOR CANCER
FROM CHILDREN'S HOSPITAL BOSTON

http://moneyam.uk-wire.com/cgi-bin/articles/200707060700517695Z.html

Medical News Today

Oxford Biomedica Secures Rights To Endostatin
http://www.medicalnewstoday.com/medicalnews.php?newsid=76265

OXFORD BIOMEDICA
NOTICE OF INTERIM RESULTS
FOR THE SIX MONTHS ENDED 30 JUNE 2007

Date: 11 September 2007



Oxford, UK - 7 August 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announces that it will be releasing its interim results for the six
months ended 30 June 2007 on Tuesday 11 September.


Analyst Briefing:

An analyst briefing will be held at 10:00 am on 11 September at the offices of
Buchanan Communications, 45 Moorfields, London EC2.


Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio
web cast of the results presentation.

To connect to the web cast facility, please go to the Company's website:

http://www.oxfordbiomedica.co.uk/

Great!! price back down to my trading target to buy, the deals over the next few mths will ensure these resume heir upward path.

robstuff
I agree, still holding.

M&G who I have great respect for as they have made me lots of money over the yrs has now got 9.3%!! and these guys know their business inside out and will have specialist pharmaceutical/biotech analysts researching the company:

"M&G Securities Limited (a wholly owned subsidiary of M&G Limited) has crossed
the 5% notifiable interest threshold. Within this change in interest, M&G
Investments Funds 3, an Open Ended Investment Company (OEIC) which is not a
Prudential group company but is included in the Prudential plc group interest,
has also crossed the 5% threshold."

I'm very confident the shares are at the bootom of this trough and should rise steeply over the coming mths. Fill ya boots!

A lot of takeover talk on the other sites, maybe a newspaper article about to recommend too.. lets see....

Hi Robstuff, thanks for the info re what's going on on other sites (which ones??). There have been rumours of takeover interest by GSK and Pfizer; I also think Sanofi-Aventis could be interested. OXB have several drug candidates in late stage of development, which is just the sort of thing to attract the big pharmacos.

I held this stock earlier in the year and have been waiting for it to bottom out before buying in again. It's been steadily rising in the past few days so I've just filled my wellington-size boots!

Toya, Advfn.com has many users and discussion threads. There is much talk of a bid coming frm Sanofi but my view is that GSK wilsnap it up before Trovax results due next y.

There's also a lot of talk of dodgy dealing with traders/mms signalling with 1 share and 2 share trades. There does seem to have been a lot of these recently!

Sticking to fundamentals and likely newsflow , these must be a very strong buy now in my opinion.

Thanks for the info, Robstuff. I must have a look at advfn.com.

What is the significance of deals fo just 1 or 2 shares? - I have thought it very odd when I've seen such trades.

From today's Independent: "Sanofi Aventis takeover hopes lift Oxford Biomedica"

OXB do have a tie-up with Sanofi on some of their drug developments (Trovax? - not had time to check) which is why I had thought they would be an obvious likely co to take over OXB.

If others are also interested (as per rumours), it could become interesting in the next few months.

OXB seems to have turned around this morning, for sure: sp up 3.12% to 37-37.25. That's around its previous resistance levels in Aug and Sept (after which it slumped to as low as 32.5). From what I'm learning (well, at least trying to assimilate) this does loook significant.





Powered by IST's

Director Buying

Oxford Biomedica PLC
22 October 2007


Oxford BioMedica plc (the 'Company')

Director Shareholdings

Oxford, UK: Oxford BioMedica plc (LSE : OXB) announces that it has been informed
that Nick Woolf, an executive director of the Company, today bought 30,000 1p
ordinary shares (0.006% of the current issued share capital) at a price of 30.5
pence per share.

Following this purchase of shares, Nick Woolf is the beneficial owner of 195,000
1p ordinary shares representing 0.036% of the Company's current issued share
capital.